Close Menu

NEW YORK (GenomeWeb) With the upcoming launch of its neurotrophic receptor tyrosine kinase (NTRK) gene fusion assay, liquid biopsy firm Circulogene is continuing to explore the use of reverse-transcriptase PCR to identify drug targets in cell-free enriched RNA.

Its new NTRK1/2/3 Fusion Test identifies up to 20 clinically relevant fusions between NTRK1/2/3 and other genes, which the firm said is important for cancers with a less than one percent NTRK-positive detection rate.  

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.

Jun
11
Sponsored by
Roche

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).